Marwa Mahmoud, Miia Juntunen, Amna Adnan, Laura Kummola, Ilkka S Junttila, Minna Kelloniemi, Tuula Tyrväinen, Heini Huhtala, Abeer I Abd El Fattah, Khalda Amr, Alaa Mohamad El Erian, Mimmi Patrikoski, Susanna Miettinen
For adipose stromal/stem cell (ASCs)-based immunomodulatory therapies, it is important to study how donor characteristics, such as obesity and type 2 diabetes (T2D), influence ASCs efficacy. Here, ASCs were obtained from two groups, donors and T2D and obesity (dASCs) or nondiabetic donors with normal-weight (ndASCs), and then cultured with anti-CD3/CD28-stimulated allogeneic CD4 T cells. ASCs were studied for the expression of the immunomodulators CD54, CD274, and indoleamine 2, 3 dioxygenase 1 (IDO) in inflammatory conditions...
March 22, 2023: Stem Cells